An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Periodic Fevers Syndrome Clinical Trial

Official title: An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF))

Status Completed

Clinical Trial Summary

The primary objective of this study was to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offered the opportunity for participants who completed Epoch 4 of the preceding CACZ885N2301 (NCT02059291) study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes was suspended.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Amyloidosis
• Familial Mediterranean Fever
• Fever
• Mevalonate Kinase Deficiency
• Periodic Fevers Syndrome
• Syndrome

• NCT number: NCT02911857
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 3
• Start date: October 3, 2016
• Completion date: January 27, 2017